Institute for Medical Education and Research, Madelyn Trupkin Herzfeld, IMER, imer, imier, Miami, Florida, Nursing CE's, Nursing contact hours, nursing education, continuing education, medical research and education, Oncology, Postgraduate credit, oncology nurses, nurses, symposia, symposium, online educational credit, Breast Cancer, Cancer, cancer, breast cancer, colorectal cancer, Colorectal Cancer, Targeting EGFR, EGFR Inhibitors, egfr inhibitors, head and neck cancer, Anti-VEGF, VEGF Inhibitors, vegf inhibitors, lung cancer, head cancer, CINV, cinv, Chemotherapy Induced Nausea & Vomiting, chemotherapy, nausea, vomiting, mucositis, cancer pain, chronic pain  
IMER Oncology Nurse Regional Tour
   
  CE REGIONAL MEETINGS FOR ONCOLOGY NURSES

IMER Regional Meeting

Comprehensive Course in Mantle Cell Lymphoma

Sponsored by:

IMER

Please see the scheduled meetings for programs in your area. This series is new neeting series.

Target Audience

This activity has been designed to meet the educational needs of oncology nurses and midlevel practitioners who care for patients with mantle cell lymphoma (MCL).

Purpose

To educate oncology registered nurses on the management of patients receiving cancer therapy with epidermal growth factor receptor (EGFR) inhibitors.

Program Overview

This educational program is designed to meet the needs of oncology professionals who treat patients with MCL. The program will begin with an overview of disease pathophysiology, diagnostic work-up, and an overview of current options for treating MCL in the front-line, relapsed, and salvage settings. In the latter portion of the program novel agents being used to treat MCL will be introduced and their mechanisms described in 3-D video animation. Data from recent clinical trials demonstrating the efficacy of such novel agents will be presented. The program will conclude with strategies for supportive care during treatment via case presentations of actual patient experiences. Program attendees will receive several clinical tools to be used for side effect assessment and management, as well as sample patient education tools, to utilize in their individual clinical practices.

Learning Objectives

Upon completion of this program, participants should be better able to:

  • Name the signature mutation associated with the pathogenesis of MCL
  • List currently recommended induction and consolidation regimens for patients with MCL
  • Describe the different strategies for autologous versus allogeneic transplant in the treatment of MCL
  • Identify currently approved regimens for treating relapsed or refractory disease
  • Name the new and emerging agents being developed to treat patients with MCL
  • Categorize how the results of recent clinical trials are being integrated into MCL management
  • Identify common toxicities of novel agents being used to treat patients with MCL
  • Distinguish algorithms for assessing and managing treatment-related peripheral neuropathy, myelosuppression, and gastrointestinal toxicities

Chairperson

Amy L. Goodrich, RN, MSN, CRNP-AC
 Johns Hopkins Kimmel Cancer Center

 

 

 

 

 

 

This activity is supported by an independent educational grant from Millennium: The Takeda Oncology Company.
 

Addtional CE Meetings on This Topic:

Click on the column headers to sort and on a city for more details.
{date} {city} {speaker}

{icon}
{location}

 

More meetings to be added in the near future. Check for updates.

Program Agenda

Program Overview 5 minutes
Disease Overview: Chemotherapy and the Role of Transplant 25 minutes
  • Pathophysiology and Disease Presentation
  • Treatment Overview: Old Standards and New Standards
  • Stem Cell Transplant for MCL: Who, When, and How?
  
New Agents and New Hope 15 minutes
  • Recent Clinical Trial Data
  • Agents in Preclinical and Phase I Testing
  
Managing Symptoms and Side Effects: Case-Based Discussions 25 minutes
  • Peripheral Neuropathies
  • Gastrointestinal Toxicities
  • Myelosuppression
  
Questions and Discussion 10 minutes

 

Disclosure of Conflicts of Interest

The Institute for Medical Education & Research (IMER) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by IMER for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Accreditation Statements

This educational activity for 1.5 contact hour will be provided by IMER. IMER is an approved provider of continuing education by the Georgia Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

IMER is approved by the California Board of Registered Nursing, Provider Number 14763 for 1.5 contact hour.

This program has been approved for 1.5 contact hour(s) of continuing education (which includes 1.1 hour(s) pharmacology) by the American Academy of Nurse Practitioners. Program ID 0801052.

Application pending approval with the American Academy of Nurse Practitioners (including pharmacology hours).

A statement of credit will be issued only upon receipt of a completed activity evaluation form.

There is no fee for this educational activity.